Document Detail


No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
MedLine Citation:
PMID:  17725414     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The present study assessed the relationship between central nervous system (CNS) side effects and plasma concentrations of efavirenz (EFV) in Japanese HIV-1-infected patients. Subjects consisted of 69 HIV-1-infected patients (57 therapy-naive and 12 therapy-experienced patients) being treated using EFV in combination with other antiretroviral agents at the outpatient HIV clinic. Successful virological treatment was achieved in 61 patients. Eight patients discontinued EFV containing therapy because CNS symptoms did not resolve (four patients), EFV-specific mutations were detected (two patients), or skin rash was observed (two patients). Mean EFV plasma concentration for 61 effectively treated patients, measured at 15 h postdosing, was 2.42 microg/ml (range: 0.78-6.82 microg/ml). This EFV concentration range contributed to suppressed viral load in these Japanese patients. Adverse CNS effects were observed in 19 patients soon after therapy onset. These effects disappeared within 1 month except for four patients who suffered severe CNS side effects. Mean EFV plasma concentrations were not significantly different between subjects with (2.45 +/- 1.08 microg/ml) and without (2.42 +/- 1.40 microg/ml) CNS side effects. We concluded no correlation existed between the plasma EFV concentration and the emergence of CNS side effects in Japanese HIV-1-infected patients. Further investigations, enforced with the drug concentration measurement at earlier time points and more appropriate assessment of CNS symptoms, are required.
Authors:
Masaaki Takahashi; Shiro Ibe; Yuichi Kudaka; Naoya Okumura; Atsushi Hirano; Tatsuo Suzuki; Naoto Mamiya; Motohiro Hamaguchi; Tsuguhiro Kaneda
Related Documents :
16504634 - Use of n-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of...
21198274 - Elevated renin levels in patients with liver cirrhosis and hepatocellular carcinoma.
8214924 - Role of atrial natriuretic factor in impaired sodium excretion of normocapnic and hyper...
4093574 - Treatment of smoke inhalation by hyperbaric oxygen.
14584384 - Involvement of interleukin-18 in severe plasmodium falciparum malaria.
23470264 - Relationship of interferon-γ-inducible protein-10 kda with viral response in patients ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  23     ISSN:  0889-2229     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-29     Completed Date:  2007-12-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  983-7     Citation Subset:  IM; X    
Affiliation:
Department of Pharmacy, National Hospital Organization Nagoya Medical Center (Tokai Area Central Hospital for AIDS Treatment and Research), Nagoya,Aichi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / adverse effects,  blood
Antiretroviral Therapy, Highly Active*
Benzoxazines / adverse effects*,  blood*,  therapeutic use
CD4 Lymphocyte Count
Central Nervous System / drug effects*
Female
HIV Infections / complications,  drug therapy*,  virology
HIV-1*
Humans
Japan
Male
Middle Aged
Viral Load
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Benzoxazines; 154635-17-3/efavirenz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV...
Next Document:  Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination...